Dear Duchenne Community, This morning we issued a press release providing a full-year 2022 business update. Among the highlights, Solid completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases, including Duchenne. IGNITE DMD Phase I/II Clinical Trial Update On March 19, Solid presented one-year post-treatment data relating ... Read more
